Can Ozempic Prevent Cancer? New Research Reveals Promising Links
GLP-1 medications like Ozempic and Wegovy may reduce cancer risk and slow tumor progression, according to over 40 studies presented at the American Society of Clinical Oncology (ASCO) meeting. Research indicates lower rates of breast, pancreatic, and lung cancers, though experts warn these observational findings require randomized clinical trials for confirmation.
Can GLP-1 drugs prevent breast cancer?
Data suggests a significant link between GLP-1 use and lower breast cancer incidence. A University of Pennsylvania analysis of more than 100,000 women found that those taking the medications developed breast cancer roughly 30% less often. This result remained consistent after researchers adjusted for age, diabetes, and obesity.
The benefits may extend to survival rates for those already diagnosed. Jasmine Sukumar of the MD Anderson Cancer Center analyzed records for 137,000 breast cancer patients between 2014 and 2023. Her findings showed a five-year post-surgery survival rate of nearly 96% for GLP-1 users, compared to about 90% for similar patients not using the drugs.
How do these medications affect other cancer types?
The potential protective effects appear to span multiple malignancies. Sarina Ailawadi of the University Hospitals Seidman Cancer Center reported that patients with chronic pancreatitis—a major risk factor for pancreatic cancer—were more than 50% less likely to develop the disease if they took GLP-1 medications.
Similar trends appeared in blood cancers. Colton Jones, a fellow at the Mays Cancer Center of the University of Texas, found a 63% reduction in the risk of acute myeloid leukemia among GLP-1 users. Jones noted that if this holds true for the 20 million Americans using these drugs, it could prevent approximately 1,500 leukemia cases.
Reducing the spread of tumors
Mark Orland of the Cleveland Clinic investigated whether these drugs slow the progression of existing cancers. His research, published in the Journal of Clinical Oncology, found that patients using GLP-1 drugs were 38% to 50% less likely to progress to metastatic disease across four types of cancer: lung, breast, colon, and liver.
Do Ozempic and Wegovy make cancer treatments more effective?
Recent findings suggest GLP-1 drugs might act as a force multiplier for existing therapies. Shalin Rawal from NYMC studied patients with metastatic colorectal cancer receiving immune-checkpoint inhibitors. Those also taking GLP-1 medications showed consistently lower mortality rates at three- and five-year marks.
In lung cancer treatment, the impact was equally stark. Khvaramze Shaverdashvili of Thomas Jefferson University analyzed 25,000 patients with metastatic non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs). The five-year survival rate for GLP-1 users was 63%, compared to 40% for non-users.
Why are these results not yet a medical certainty?
Most of the ASCO findings rely on observational data. This means researchers identified correlations in medical records rather than proving cause-and-effect in a controlled environment. Doctors warn that patients who take GLP-1 drugs may differ from non-users in ways that statistics cannot fully capture.
Medical historians point to Metformin as a cautionary tale. In the 2010s, observational studies repeatedly linked the diabetes drug to lower cancer risks. However, those benefits largely vanished when the drug was tested in randomized clinical trials.
Researchers believe the drugs may work independently of weight loss. According to Mark Orland, anti-inflammatory and immunomodulating effects may make it harder for cancer cells to thrive and spread. Gilberto de Lima Lopes of the University of Miami described the medications as behaving like “longevity drugs” that influence broad biological processes.
Comparative Survival Outcomes
The data from ASCO highlights a consistent gap in survival and progression rates between GLP-1 users and non-users across different therapies:
| Cancer Type/Treatment | Non-User Outcome | GLP-1 User Outcome |
|---|---|---|
| Breast Cancer (5-yr survival) | ~90% | ~96% |
| Lung Cancer w/ TKIs (5-yr survival) | 40% | 63% |
| Metastatic Progression (General) | Baseline | 38% to 50% Reduction |
Frequently Asked Questions
Should I take Ozempic to prevent cancer?
No. Doctors state the evidence is not yet strong enough to prescribe these medications for cancer prevention. They are currently approved for diabetes and weight management.
Do these drugs work only by helping people lose weight?
Not necessarily. Researchers believe GLP-1 drugs may reduce inflammation and alter metabolic pathways that directly hinder tumor growth, regardless of weight loss.
Which cancers showed the most promise in these studies?
The most significant signals appeared in breast, pancreatic, lung, and colorectal cancers, as well as acute myeloid leukemia.
What do you think about the expansion of GLP-1 uses? Share your thoughts in the comments or subscribe to our newsletter for the latest medical research updates.